- Conditions
- Allergic Conjunctivitis
- Interventions
- Olopatadine hydrochloride ophthalmic solution, 0.2%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–30
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Allergic Conjunctivitis
- Interventions
- Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Allergic Conjunctivitis
- Interventions
- olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale, Placebo
- Drug
- Lead sponsor
- Andover Research Eye Institute
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- GSP 301 NS, Olopatadine HCl NS, Mometasone furoate NS, GSP 301 Placebo NS
- Drug
- Lead sponsor
- Glenmark Specialty S.A.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 37
- States / cities
- Mission Viejo, California • San Diego, California • San Jose, California + 28 more
- Conditions
- Normal Ocular Health
- Interventions
- AC-170 0.17%, AC-170 0.24% (Formulation 1), AC-170 0.24% (Formulation 2), Olopatadine hydrochloride 0.2%/Tears Naturale II
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts